Study of BLU-808 in Allergic Rhinoconjunctivitis

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).

Timeline

Start

2025-04-14

Primary completion

2025-09-08

Completion

2025-09-08

Drugs

Indications